4 months ago
NBIX
AnalystsAndrew S. FeinAndrew S. Fein's Stock Forecasts
AnalystsAndrew S. Fein
Analyst Ranking
Top 11%
#544 out of 5308 analysts
Average Return
+21.43%
Win Rate
60%41 out of 68
Risk vs Reward
Poor
Good
Andrew S. Fein's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Day One Biopharmaceuticals IncDAWN | +271.21% | $5.80 | $21.53 | 2025-08-05 - 2026-04-23 | Buy |
Liquidia CorpLQDA | +236.48% | $22.86 | $76.92 | 2025-10-05 - 2026-06-25 | Buy |
Palvella Therapeutics IncPVLA | +187.95% | $47.30 | $136.20 | 2025-08-14 - 2026-06-25 | Buy |
Liquidia CorpLQDA | +175.60% | $27.91 | $76.92 | 2025-11-03 - 2026-06-25 | Buy |
Palvella Therapeutics IncPVLA | +136.09% | $57.69 | $136.20 | 2025-09-24 - 2026-06-25 | Buy |
Andrew S. Fein Analyst Color
Get additional color on Andrew S. Fein's coverage of popular stocks
6 months ago
BCRX
Andrew S. Fein's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Liquidia CorpLQDA | 5 | Buy | $75.00 | -2.50% | Maintains | 21 days ago |
Fulcrum Therapeutics IncFULC | 4 | Hold | $3.00 | -16.90% | Downgrades | 24 days ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Hold | $31.50 | +0.25% | Downgrades | a month ago |
Wave Life Sciences LtdWVE | 5 | Buy | $13.00 | +126.09% | Maintains | a month ago |
Metavia IncMTVA | 4 | Buy | $20.00 | +1,207.19% | Reiterates | a month ago |
Madrigal Pharmaceuticals IncMDGL | 4 | Buy | $620.00 | +20.67% | Reiterates | 2 months ago |
Kalvista Pharmaceuticals IncKALV | 1 | Hold | $27.00 | 0.00% | Downgrades | 2 months ago |
Aura Biosciences IncAURA | 1 | Buy | $24.00 | +249.85% | Maintains | 2 months ago |
Protara Therapeutics IncTARA | 1 | Buy | $27.00 | +575.00% | Maintains | 2 months ago |
Neurocrine Biosciences IncNBIX | 3 | Buy | $215.00 | +30.95% | Maintains | 3 months ago |
Biogen IncBIIB | 2 | Buy | $237.00 | +17.35% | Maintains | 3 months ago |
United Therapeutics CorpUTHR | 3 | Buy | $660.00 | +21.46% | Maintains | 3 months ago |
Insmed IncINSM | 4 | Buy | $245.00 | +134.52% | Maintains | 3 months ago |
Denali Therapeutics IncDNLI | 1 | Buy | $42.00 | +69.83% | Maintains | 3 months ago |
Amylyx Pharmaceuticals IncAMLX | 3 | Buy | $34.00 | +94.95% | Reiterates | 3 months ago |
Palvella Therapeutics IncPVLA | 6 | Buy | $270.00 | +98.24% | Maintains | 3 months ago |
Vertex Pharmaceuticals IncVRTX | 4 | Buy | $641.00 | +33.49% | Maintains | 4 months ago |
Savara IncSVRA | 3 | Buy | $10.00 | +65.84% | Maintains | 6 months ago |
Dbv Technologies SaDBVT | 3 | Buy | $40.00 | +149.69% | Maintains | 6 months ago |
Biocryst Pharmaceuticals IncBCRX | 1 | Buy | $32.00 | +223.23% | Maintains | 6 months ago |
Kymera Therapeutics IncKYMR | 3 | Buy | $134.00 | +15.06% | Maintains | 7 months ago |
Kamada LtdKMDA | 1 | Buy | $13.00 | +81.06% | Maintains | 7 months ago |
Arcturus Therapeutics Holdings IncARCT | 3 | Hold | $9.00 | +31.96% | Maintains | 7 months ago |
Prothena Corp Public Ltd CoPRTA | 3 | Buy | $30.00 | +223.62% | Maintains | 8 months ago |
Akero Therapeutics IncAKRO | 2 | Hold | $54.00 | -1.19% | Downgrades | 9 months ago |
89bio IncETNB | 2 | Hold | $14.50 | -2.29% | Downgrades | 9 months ago |
Terns Pharmaceuticals IncTERN | 1 | Hold | $7.44 | -85.95% | Assumes | 10 months ago |
Arvinas IncARVN | 1 | Buy | $18.00 | +124.16% | Maintains | a year ago |
Day One Biopharmaceuticals IncDAWN | 1 | Buy | $25.00 | +16.12% | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.